A photo of Theodosia A. Kalfa.

Co-Director, Erythrocyte Diagnostic Laboratory

Professor, UC Department of Pediatrics

513-636-0989

513-636-3549

Board Certified

My Biography & Research

Additional Languages

Greek

Research Interests

Signaling in erythrocytes; erythropoiesis; sickle cell disease; reactive oxygen species

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Sickle Cell and Hemoglobin Disorders

Research Divisions

Experimental Hematology and Cancer Biology, Hematology, Cancer and Blood Diseases



Blog Posts

My Locations

My Education

MD: Aristotle University Medical School, Thessaloniki, Greece, 1990.

PhD: Aristotle University Medical School, Thessaloniki, Greece, 1997.

Residency: University Of North Carolina, Chapel Hill, NC, 1999.

Fellowship: Duke University Medical Center, Durham, NC, 2003.

Certification: Hematology / oncology, American Board of Pediatrics, 2004; Pediatrics, American Board of Pediatrics, 2000; ECFMG Certification, 1995.

Licenses: Full and unrestricted medical license (OH Medical Board), 2003-present; full and unrestricted license of medical practice in Greece, 1990-present.

My Publications

Selected Publication

VPS4A Mutations in Humans Cause Syndromic Congenital Dyserythropoietic Anemia due to Cytokinesis and Trafficking Defects. Seu, KG; Trump, LR; Emberesh, S; Lorsbach, RB; Johnson, C; Meznarich, J; Underhill, HR; Chou, ST; Sakthivel, H; Nassar, NN; et al. The American Journal of Human Genetics. 2020; 107:1149-1156.

Red cell membrane disorders: structure meets function. Risinger, M; Kalfa, TA. Blood. 2020; 136:1250-1261.

Signaling and cytoskeletal requirements in erythroblast enucleation. Konstantinidis, DG; Pushkaran, S; Johnson, JF; Cancelas, JA; Manganaris, S; Harris, CE; Williams, DA; Zheng, Y; Kalfa, TA. Blood. 2012; 119:6118-6127.

A painless erythematous swelling of the external ear as a manifestation of Lyme disease: A case report. Remiker, A; Haslam, D; Kalfa, TA. Journal of Medical Case Reports. 2020; 14.

How I approach hereditary hemolytic anemia and splenectomy. Rothman, JA; Stevens, JL; Gray, FL; Kalfa, TA. Pediatric Blood and Cancer. 2020; 67.

Inhibition of Band 3 tyrosine phosphorylation: a new mechanism for treatment of sickle cell disease. Noomuna, P; Risinger, M; Zhou, S; Seu, K; Man, Y; An, R; Sheik, DA; Wan, J; Little, JA; Gurkan, UA; et al. British Journal of Haematology. 2020; 190:599-609.

Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. McGann, PT; Niss, O; Dong, M; Marahatta, A; Howard, TA; Mizuno, T; Lane, A; Kalfa, TA; Malik, P; Quinn, CT; et al. American Journal of Hematology. 2019; 94:871-879.

The Spectrum of SPTA1-Associated Hereditary Spherocytosis. Chonat, S; Risinger, M; Sakthivel, H; Niss, O; Rothman, JA; Hsieh, L; Chou, ST; Kwiatkowski, JL; Khandros, E; Gorman, MF; et al. Frontiers in Physiology. 2019; 10.

Rare Hereditary Hemolytic Anemias Diagnostic Approach and Considerations in Management. Risinger, M; Emberesh, M; Kalfa, TA. Hematology/Oncology Clinics of North America. 2019; 33:373-392.

Hereditary elliptocytosis-associated alpha-spectrin mutation p.L155dup as a modifier of sickle cell disease severity. Risinger, M; Christakopoulos, GE; Schultz, CL; McGann, PT; Zhang, W; Kalfa, TA. Pediatric Blood and Cancer. 2019; 66:e27531-e27531.